YF-VAX is prepared by culturing the 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken embryos. The vaccine contains sorbitol and gelatin as a stabilizer, is lyophilized, and is hermetically sealed under nitrogen.
YF-VAX is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older.
YF-VAX is administered as a single subcutaneous injection of 0.5 mL of reconstituted vaccine. Do not administer YF-VAX by intravascular, intramuscular, or intradermal routes.
A single dose provides protection for 10 years for most people.
Sanofi Pasteur’s new state-of-the-art YF-VAX production facility has been licensed by the U.S. FDA and the transition of production continues.
Vaccination with YF-VAX is contraindicated in infants less than 9 months of age due to an increased risk of encephalitis.
Additionally, vaccination with YF-VAX is also contraindicated in lactating women who are providing breastmilk to infants less than 9 months of age due to the potential for transmission of the vaccine virus in breastmilk.
Sanofi Pasteur, the manufacturer of the only yellow fever vaccine (YF-Vax) licensed in the United States, expects to provide an update by the end of 2019 on the return to supply YF-Vax.